trial failure
Kodiak’s Eye Drug Revival Spurs Renewed FDA Approval Bid
Kodiak Sciences had previously abandoned its tarcocimab tedromer program following disappointing results in two phase 3 trials. However, a recent ...
Omeros halts phase 3 trial of kidney disease drug after disappointing results, stock plummets
In a surprising turn of events, Omeros has halted its phase 3 trial of narsoplimab in kidney disease patients, as ...
Magrolimab fails to improve survival in leukemia, Gilead halts trial
Another failure has occurred in Gilead Sciences’ $4.9 billion immuno-oncology wager. Following an ad hoc analysis of a phase 3 ...
Galecto slashes workforce, explores options after failed fibrosis trial
Boston-based biotech firm Galecto is facing a significant workforce reduction of 70%, affecting 29 employees, following the discontinuation of its ...
Relmada reports positive results from open-label trial of REL-1017 for major depressive disorder
Relmada Therapeutics, a central-nervous-system-focused biotech company, has finally glimpsed a ray of optimism after facing setbacks in two phase 3 ...
Guard shares soar as new data show clinical benefit despite missing primary endpoint
Guard Therapeutics is staging a remarkable recovery following a setback in its phase 2 clinical trial for kidney injury treatment. ...
